Navigation Links
Pearl Therapeutics Completes Phase 2b Study of Glycopyrrolate, Defines Dose-Response Curve and Identifies Optimal Dose of PT001
Date:9/13/2012

REDWOOD CITY, Calif., Sept. 13, 2012 /PRNewswire/ -- Pearl Therapeutics Inc. today announced the completion of a randomized, double-blind Phase 2b dose-ranging study in which six doses of the long-acting muscarinic antagonist (LAMA), glycopyrrolate (GP) ranging from 18 micrograms to 600 nanograms BID were delivered via metered-dose inhaler (GP MDI; PT001) to patients with moderate-to-severe COPD. In this study (NCT01566773) and the previously conducted dose-ranging GP MDI studies, a total of nine descending doses (a 240-fold range) of GP have been evaluated. The results, which Pearl plans to present at appropriate medical meetings in 2013, identify doses that are believed to be the lowest effective and optimal doses of GP MDI. Further, they support progression in combination with BID formoterol fumarate (FF MDI, PT005), the LABA component of Pearl's fixed dose bronchodilator combination PT003 (GFF MDI) towards a Phase 3 program.

"By taking full advantage of the flexibility of our porous-particle-based co-suspension MDI formulation platform, we were able to assess doses of GP MDI as low as 600 nanograms, allowing us to characterize fully the dose-response curve of GP MDI. To our knowledge, this is the first time that doses of a LAMA MDI this low have been able to be studied," commented Colin Reisner, chief medical officer and executive vice president of clinical development for Pearl Therapeutics. "These GP MDI dose-ranging results strengthen our confidence in dose selection of this potent bronchodilator and demonstrate our commitment to satisfying the most stringent regulatory expectations."

"The identification of an optimal BID dose of GP MDI complements Pearl's earlier clinical findings in which the optimal BID dose of FF MDI was determined," added Chuck Bramlage, chief executive officer for Pearl Therapeutics. "We have made exceptional progress over a relatively short period of time – completing nine studies in four years – developing and testing an array of monotherapy MDIs as well as fixed dose combination MDIs to ensure that the most appropriate dose and dosing regimen were selected in advance of pivotal trials. With the upcoming completion of this comprehensive Phase 2 program, we are preparing to transition rapidly to Phase 3 to valuate safety and efficacy of PT003 in COPD patients."

Pearl's tenth study (NCT01587079) is ongoing, and is designed to quantify the additive benefit of low doses of GP in fixed-dose combination with FF. Results of this trial are expected to provide preliminary evidence for the U.S. regulatory requirement known as the "combination rule," which requires sponsors to demonstrate that each component of a fixed dose combination makes a contribution to the clinical activity of the combination product, and that the combination product is superior to each component alone. This study is expected to conclude in the third quarter of 2012, with data also being submitted for presentation at appropriate medical meetings in 2013.

About COPD
Chronic obstructive pulmonary disease (COPD) is a preventable and treatable lung disease that is the fourth leading cause of death in the United States. Each year 12 million Americans are diagnosed with COPD and an additional 12 million Americans may have COPD but remain undiagnosed. Research shows that many do not get optimal treatment.

Bronchodilator medications are central to symptom management and are prescribed on an as-needed or regular basis to prevent or reduce symptoms. Long-acting inhaled bronchodilators have been shown to be most effective and convenient. Combining bronchodilators of different pharmacological classes, as recommended by The Global Initiative for Chronic Obstructive Lung Diseases (GOLD), has been shown to improve efficacy and may decrease the risk of side effects compared to increasing the dose of a single bronchodilator. As the course of COPD progresses, regular treatment with inhaled glucocorticosteroids may be added to bronchodilator treatment.

About Pearl Therapeutics
Pearl Therapeutics is a privately held company developing combination therapies for the treatment of highly prevalent respiratory diseases, including chronic obstructive pulmonary disease and asthma. Pearl is rapidly advancing a pipeline of products including PT003, an inhaled, fixed-dose combination bronchodilator product comprised of a long-acting muscarinic antagonist (LAMA) and a long-acting beta-2 agonist (LABA) delivered via a metered dose inhaler (HFA MDI); and PT010, a triple-combination product that combines the LAMA and LABA components of PT003 with an inhaled corticosteroid (ICS) for twice-daily administration from an HFA MDI for the treatment of severe COPD. Both PT003 and PT010 are developed with Pearl's proprietary porous particle co-suspension technology, which allows the formulation of multiple products in the MDI format, with highly stable, robust and aerodynamically efficient drug delivery. Founded in 2006, Pearl Therapeutics is privately held and backed by 5AM Ventures, Clarus Ventures, New Leaf Ventures and Vatera Healthcare. For more information, please visit www.pearltherapeutics.com.


'/>"/>
SOURCE Pearl Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Anthera Pharmaceuticals Provides Additional Data from the Recently Completed PEARL-SC Study of Blisibimod in the Proposed Phase 3 Population
2. Anthera Updates Phase 3 Plans Following Results from the Phase 2b PEARL-SC Dose Ranging Study of Blisibimod
3. NFLPA and THERAPEARL, LLC Partner to Provide Athletes with Game Changing Innovations in Hot and Cold Pack Therapy
4. Pearl Therapeutics Phase 2b Twice-Daily Dosing Data Suggest Morning and Evening Benefit of PT003 in Patients with COPD
5. Heraeus Launches Remarkably Smooth Venus® Pearl Composite
6. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
7. RNL BIO, a South Korean adult stem cell firm, introduces its autologous stem cell therapeutics in Turkey to treat patients with various intractable diseases
8. Healthpoint Biotherapeutics Initiates Phase III Study of Unique Investigational Cell-Based Therapy for Venous Leg Ulcers
9. Novelos Therapeutics Successfully Completes Second Cohort In Phase 1b Solid Tumor Trial With I-131-CLR1404 (HOT) Cancer-Targeted Molecular Radiotherapeutic
10. Sorbent Therapeutics Presents CLP1001 Phase 2a Study Results at the 16th Annual Meeting of the Heart Failure Society of America
11. Novelos Therapeutics And Academic Collaborators Present Three Posters At 2012 World Molecular Imaging Congress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/19/2016)... 2016 , The data will be ... # 8006)   The conclusions of the study ... treated patients with 90% of the m presenting ... . Seventy two percent of the patients had clinical benefit. ... results from a Phase I study of plitidepsin in combination with bortezomib and ...
(Date:5/19/2016)... , May 19, 2016 ... titled, World Biopsy Devices Market Opportunities and Forecasts, ... devices market generated $1,621 million in 2015. The ... 2015, and is expected to maintain this trend ... http://photos.prnewswire.com/prnh/20140911/647229 ) , To ...
(Date:5/19/2016)... 19, 2016 MGB Biopharma, ... of Anti-infectives, Welcomes the Final Instalment of Lord ... Today   Lord Jim O,Neill,s ... final recommendations, providing a comprehensive action plan for ... the rising threat of superbugs - something that ...
Breaking Medicine Technology:
(Date:5/23/2016)... ... May 23, 2016 , ... California State University Northridge ... quality of life and is currently focusing on ways to improve how people ... tested through research to find out whether watching them could have a significant ...
(Date:5/23/2016)... ... 2016 , ... During Logan University’s (Logan) Spring ... awarded $6,000 in chiropractic scholarships. The winners of the three $2,000 scholarships ... fifth trimester of classes at Logan. , “Standard Process has been extremely generous ...
(Date:5/23/2016)... ... May 23, 2016 , ... Hospice of Westchester (HOW), ... for over 24 years, recently hosted its sixth annual Celebration of Life Memorial ... remembrance ceremonies, each concluding with the release of Monarch butterflies that honored the ...
(Date:5/23/2016)... ... 23, 2016 , ... Bio-Optronics, Inc. is delighted to announce ... its recent and anticipated growth. , Max Elbaz was appointed as Vice President, ... segments. Max joined the Bio-Optronics team in March. His areas of expertise include ...
(Date:5/23/2016)... ... May 23, 2016 , ... While new ... epidemic (1), physicians are not legally required to follow them. In the absence ... 3, 4). Novus Medical Detox Center , a leading Florida-based drug treatment ...
Breaking Medicine News(10 mins):